Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 42Breast 41Genitourinary 36Gynecologic 21Other 20Thoracic 19Head & Neck 19CNS 13Other hematologic neoplasm 8Lymphoid 8Dermatologic 7Tumor-Agnostic 6Sarcoma 6Plasma cell 3Other solid neoplasm 3Endocrine 3NET 2Classical hematology 2Other neoplasm 1

Conditions

Neuroendocrine Tumors 2

Interventions

lutetium Lu 177 dotatate 32Everolimus 19Magnetic Resonance Spectroscopy 14gallium Ga 68 dotatate 12Temozolomide 12Nivolumab 11Capecitabine 10pembrolizumab 9lanreotide 9cabozantinib 8Positron Emission Tomography Computed Tomography 8177Lu-octreotide, DOTA(0)-Tyr(3)- 8Ga(III)-DOTATOC 73-Iodobenzylguanidine 7Somatostatin 6Octreotide 6Lutetium-177 6Carboplatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5surufatinib 5lenvatinib 5Ipilimumab 5Fluorodeoxyglucose F18 5pasireotide 4copper dotatate CU-64 4avelumab 4Single Photon Emission Computed Tomography Computed Tomography 4Positron-Emission Tomography 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Metformin × NET × Clear all
NCT02823691 2021-06-07

MetNET-2

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase EARLY_PHASE1 Unknown
20 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02279758 2014-10-31

MetNet

Instituto do Cancer do Estado de São Paulo

Phase 2 Unknown
30 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡